학술논문
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Document Type
Article
Author
Williams, Bryan; Turner, Rebecca; Libri, Vincenzo; Mussai, Francis; Middleton, Gary; Bowden, Sarah; Bangash, Mansoor; Gao-Smith, Fang; Patel, Jaimin; Sapey, Elizabeth; Thomas, Mark; Coles, Mark; Watkinson, Peter; Rahman, Naj; Angus, Brian; Mentzer, Alexander J.; Novak, Alex; Feldman, Marc; Richter, Alex; Faustini, Sian; Bathurst, Camilla; Van de Wiel, Joseph; Mee, Susie; James, Karen; Rahman, Bushra; Turner, Karen; Hill, Adam; Gordon, Anthony; Yap, Christina; Matthay, Michael; McAuley, Danny; Hall, Andrew; Dark, Paul; McMichael, Andrew; Fisher, Benjamin A ; Veenith, Tonny ; Slade, Daniel ; Gaskell, Charlotte; Rowland, Matthew; Whitehouse, Tony; Scriven, James; Parekh, Dhruv; Balasubramaniam, Madhu S; Cooke, Graham; Morley, Nick; Gabriel, Zoe; Wise, Matthew P; Porter, Joanna; McShane, Helen; Ho, Ling-Pei; Newsome, Philip N; Rowe, Anna; Sharpe, Rowena; Thickett, David R; Bion, Julian; Gates, Simon; Richards, Duncan; Kearns, Pamela
Source
In The Lancet Respiratory Medicine March 2022 10(3):255-266
Subject
Language
ISSN
2213-2600